Vitamin K epoxide reductase complex subunit 1 gene polymorphism is associated with atherothrombotic complication after drug-eluting stent implantation: 2-Center prospective cohort study

American Heart Journal

Volumn 157, Issue 5, 2009, Pages 908-912

  Suh, Jung Won ^a   Baek, Sang Hong ^b   Park, Jin Shik ^a   Kang, Hyun Jae ^a   Chae, In Ho ^a   Choi, Dong Ju ^a   Park, Hun Jun ^b   Kim, Pum Joon ^b   Seung, Ki Bae ^b   Kim, Hyo Soo ^a  

^a Seoul National University College of Medicine   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; PACLITAXEL; PROTEIN; RAPAMYCIN; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX 1; ZOTAROLIMUS;

ADULT; AGED; ARTERY DISEASE; ARTICLE; ATHEROTHROMBOSIS; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG ELUTING STENT; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GENE; GENE LOCUS; GENETIC POLYMORPHISM; GENOTYPE; HAZARD RATIO; HEART DEATH; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL ANALYSIS; STENT THROMBOSIS; STROKE; SURVIVAL RATE; VKORC1 GENE;

ATHEROSCLEROSIS; CORONARY DISEASE; DNA; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; KOREA; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; MYOCARDIAL REVASCULARIZATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; SURVIVAL RATE; THROMBOSIS; TIME FACTORS;

EID: 64449087852     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2009.02.001     Document Type: Article

References (21)

1. Taubman M.B., Fallon J.T., Schecter A.D., et al. Tissue factor in the pathogenesis of atherosclerosis. Thromb Haemost 78 (1997) 200-204
2. Lima L.M., Sousa M.O., Dusse L.M., et al. Tissue factor and tissue factor pathway inhibitor levels in coronary artery disease: correlation with the severity of atheromatosis. Thromb Res 121 (2007) 283-287
3. Tutar E., Ozcan M., Kilickap M., et al. Elevated whole-blood tissue factor procoagulant activity as a marker of restenosis after percutaneous transluminal coronary angioplasty and stent implantation. Circulation 108 (2003) 1581-1584
4. Palmerini T., Coller B.S., Cervi V., et al. Monocyte-derived tissue factor contributes to stent thrombosis in an in vitro system. J Am Coll Cardiol 44 (2004) 1500-1507
5. Moons A.H., Levi M., and Peters R.J. Tissue factor and coronary artery disease. Cardiovasc Res 53 (2002) 313-325
6. Spronk H.M. Vitamin K epoxide reductase complex and vascular calcifications: is this the important link between vitamin K and the arterial vessel wall?. Circulation 113 (2006) 1550-1552
7. Oldenburg J., Watzka M., Rost S., et al. VKORC1: molecular target of coumarins. J Thromb Haemost 5 Suppl 1 (2007) 1-6
8. D'Andrea G., D'Ambrosio R.L., Di Perna P., et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105 (2005) 645-649
9. Rieder M.J., Reiner A.P., Gage B.F., et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Eng J Med 352 (2005) 2285-2293
10. Schwarz U.I., Ritchie M.D., Bradford Y., et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 358 (2008) 999-1008
11. Wang Y., Zhang W., Zhang Y., et al. VKORC1 haplotypes are associated with arterial vascular diseases (stroke, coronary heart disease, and aortic dissection). Circulation 113 (2006) 1615-1621
12. Teichert M., Visser L.E., van Schaik R.H., et al. Vitamin K epoxide reductase complex subunit 1 (VKORC1) polymorphism and aortic calcification. The Rotterdam Study. Arterioscler Thromb Vasc Biol 28 (2008) 771-776
13. Syvänen A.C. Toward genome-wide SNP genotyping. Nat Genet 37 (2005) S5-S10
14. Gunderson K.L., Steemers F.J., Lee G., et al. A genome-wide scalable SNP genotyping assay using microarray technology. Nat Genet 37 (2005) 549-554
15. Braunwald E., Antman E., Beasley J., et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation 106 (2002) 1893-1900
16. Cutlip D.E., Windecker S., Mehran R., et al. Clinical end points in coronary stent trials. Circulation 115 (2007) 2344-2351
17. Hindorff L.A., Heckbert S.R., Smith N., et al. Common VKORC1 variants are not associated with arterial or venous thrombosis. J Thormb Haemost 5 (2007) 2025-2027
18. Steffel J., Luscher T.F., and Tanner F.C. Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications. Circulation 113 (2006) 722-731
19. Steffel J., Latini R.A., Akhmedov A., et al. Rapamycin, but not FK-506, increases endothelial tissue factor expression: implications for drug-eluting stent design. Circulation 112 (2005) 2002-2011
20. Stähli B.E., Camici G.G., Steffel J., et al. Paclitaxel enhances thrombin-induced endothelial tissue factor expression via c-Jun terminal NH2 kinase activation. Cir Res 99 (2006) 149-155
21. Lüscher T.F., Steffel J., Eberli F.R., et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 115 (2007) 1051-1058